- Conditions
- Alzheimer Disease
- Interventions
- Simufilam, Placebo
- Drug
- Lead sponsor
- Cassava Sciences, Inc.
- Industry
- Eligibility
- 50 Years to 87 Years
- Enrollment
- 1,125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 65
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 57 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 109
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Alzheimer Disease
- Interventions
- Xanomeline/Trospium Chloride Capsule, Xanomeline Enteric Capsule, Placebo
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 55 Years to 90 Years
- Enrollment
- 426 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 41
- States / cities
- Scottsdale, Arizona • Anaheim, California • Fresno, California + 33 more
- Conditions
- Alzheimer's Disease, Central Nervous System Diseases, Cognition
- Interventions
- EVP-6124, Placebo
- Drug
- Lead sponsor
- FORUM Pharmaceuticals Inc
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 409 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 25
- States / cities
- Phoenix, Arizona • Chino, California • Costa Mesa, California + 21 more
- Conditions
- Agitation in Patients With Dementia of the Alzheimer's Type
- Interventions
- AVP-786, Placebo
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 387 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 111
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 78 more
- Conditions
- Alzheimer Disease
- Interventions
- Simufilam
- Drug
- Lead sponsor
- Cassava Sciences, Inc.
- Industry
- Eligibility
- 51 Years to 89 Years
- Enrollment
- 1,081 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 107
- States / cities
- Chandler, Arizona • Gilbert, Arizona • Phoenix, Arizona + 94 more
- Conditions
- Preclinical Alzheimer's Disease, Early Preclinical Alzheimer's Disease
- Interventions
- Lecanemab, Placebo
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 55 Years to 80 Years
- Enrollment
- 1,400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2031
- U.S. locations
- 72
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 61 more
- Conditions
- Agitation, Alzheimer's Type Dementia
- Interventions
- Masupirdine 50 mg, Masupirdine 100 mg, Placebo
- Drug
- Lead sponsor
- Suven Life Sciences Limited
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 375 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 27
- States / cities
- Anaheim, California • Costa Mesa, California • Encino, California + 17 more
- Conditions
- Psychosis Associated With Alzheimer's Disease
- Interventions
- KarXT, Placebo
- Drug
- Lead sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Industry
- Eligibility
- 55 Years to 90 Years
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 70
- States / cities
- Chandler, Arizona • Phoenix, Arizona • Anaheim, California + 43 more
- Conditions
- Alzheimer´s Disease
- Interventions
- Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 400 mg/kg, Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 200 mg/kg, Placebo solution: Human Albumin 0.25% - 4 mL/kg, Placebo solution: Human Albumin 0.25% - 2 mL/kg
- Biological
- Lead sponsor
- Baxalta now part of Shire
- Industry
- Eligibility
- 50 Years to 89 Years
- Enrollment
- 390 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 37
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 34 more
- Conditions
- Alzheimer's Disease, Dementia
- Interventions
- Drug: EVP-6124, Placebo
- Drug
- Lead sponsor
- FORUM Pharmaceuticals Inc
- Industry
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 474 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 44
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Costa Mesa, California + 41 more
- Conditions
- Transthyretin (TTR) Amyloid Cardiomyopathy
- Interventions
- Tafamidis, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 441 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 50
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 24 more
- Conditions
- Alzheimer's Disease, Dementia
- Interventions
- Drug: EVP-6124, Placebo
- Drug
- Lead sponsor
- FORUM Pharmaceuticals Inc
- Industry
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 403 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 42
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • Culver City, California + 39 more
- Conditions
- Alzheimer's Disease
- Interventions
- caprylic triglyceride, long-chain triglyceride
- Drug
- Lead sponsor
- Cerecin
- Industry
- Eligibility
- 55 Years to 85 Years
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- St. Petersburg, Florida
- Conditions
- Alzheimer Disease
- Interventions
- TRx0237 16 mg/day, Control, TRx0237 8 mg/day
- Drug
- Lead sponsor
- TauRx Therapeutics Ltd
- Industry
- Eligibility
- Up to 90 Years
- Enrollment
- 598 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 60
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 44 more
- Conditions
- Agitation Associated With, Alzheimer's Disease, Alzheimer's Type, Mental Disorder, Nervous System Diseases
- Interventions
- Brexpiprazole, OPC-34712
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 55 Years to 90 Years
- Enrollment
- 270 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 28
- States / cities
- Imperial, California • Lakewood, California • Long Beach, California + 21 more
- Conditions
- Agitation Associated With Alzheimer's Disease Dementia
- Interventions
- EXV-802, Placebo, EXV-801
- Drug
- Lead sponsor
- Exciva GmbH
- Industry
- Eligibility
- 55 Years to 90 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 9
- States / cities
- Murrieta, California • Indianapolis, Indiana • Flowood, Mississippi + 6 more
- Conditions
- Primary Progressive Aphasia
- Interventions
- Communication Bridge™, Evidence-Based Impairment Focused
- Behavioral
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Alzheimer's Disease, Mild Cognitive Impairment
- Interventions
- Active Lighting Intervention, Control Lighting Intervention
- Device
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 55 Years and older
- Enrollment
- 101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 2
- States / cities
- Menands, New York • New York, New York
- Conditions
- Alzheimer Disease, Agitation
- Interventions
- KarXT, KarX-EC
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 55 Years to 90 Years
- Enrollment
- 650 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 42
- States / cities
- Chandler, Arizona • Scottsdale, Arizona • Anaheim, California + 37 more
- Conditions
- Alzheimer Disease
- Interventions
- NE3107, Placebo
- Drug
- Lead sponsor
- BioVie Inc.
- Industry
- Eligibility
- 60 Years to 85 Years
- Enrollment
- 439 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Brain Health
- Interventions
- Docosahexaenoic acid
- Dietary Supplement
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 55 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Mild Cognitive Impairment (MCI), Alzheimer Disease
- Interventions
- Donanemab, Aducanumab
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 148 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 31
- States / cities
- Fullerton, California • Irvine, California • Sherman Oaks, California + 27 more
- Conditions
- Alzheimer's Disease
- Interventions
- Xanomeline/Trospium Chloride Capsule, Xanomeline Enteric Capsule, Placebo
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 55 Years to 90 Years
- Enrollment
- 426 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 42
- States / cities
- Chandler, Arizona • Garden Grove, California • Long Beach, California + 35 more
- Conditions
- Alzheimer Disease
- Interventions
- [18F]RO-948, 18F-MK6240, 18F-GTP1
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 50 Years to 100 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- St Louis, Missouri